Jeffrey S. Weber
0000-0002-4962-2957
Publication & Citation Trends
Most Cited Works
Publications
1,150 total
Artificial Intelligence Algorithm Predicts Response to Immune Checkpoint Inhibitors
Cited by 2
Semantic Scholar
Abstract 4703: EGFR is a promising therapeutic target in NF1 mutant melanoma
Cited by 0
Semantic Scholar
Abstract 6411: The gut microbiome is associated with recurrence free survival in patients with resected Stage III or Stage IV melanoma treated with immune checkpoint inhibitors
Cited by 0
Semantic Scholar
Tyrosine-protein kinase SYK-related gene signature in baseline immune cells associated with adjuvant immunotherapy-induced immune-related adverse events in melanoma.
Cited by 5
Semantic Scholar
Abstract 1185: Novel association of an autoimmune-related axis and anti-CTLA-4-based toxicities in adjuvant immunotherapy-treated melanoma patients
Cited by 0
Semantic Scholar
Predictive and pharmacodynamic biomarkers for combination therapy in stage III-IV melanoma: A Simon phase II trial (NCT03999749).
Cited by 1
Semantic Scholar
Gut microbiome is associated with recurrence-free survival in patients with resected Stage IIIB-D or Stage IV melanoma treated with immune checkpoint inhibitors OA
Cited by 3
Semantic Scholar
Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data OA
Cited by 1
Semantic Scholar
Research Topics
Cancer Immunotherapy and Biomarkers
(536)
CAR-T cell therapy research
(445)
Immunotherapy and Immune Responses
(354)
Melanoma and MAPK Pathways
(211)
Cutaneous Melanoma Detection and Management
(107)
Frequent Co-Authors
Affiliations
Université Claude Bernard Lyon 1
Université Paris-Sud
Karlsruhe Institute of Technology
University of Southern California
Roche (Switzerland)